Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter Kraft, Ph.D.

Co-Author

This page shows the publications co-authored by Peter Kraft and A Eliassen.
Connection Strength

3.499
  1. Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. J Clin Oncol. 2021 Aug 10; 39(23):2564-2573.
    View in: PubMed
    Score: 0.245
  2. A lipid-related metabolomic pattern of diet quality. Am J Clin Nutr. 2020 12 10; 112(6):1613-1630.
    View in: PubMed
    Score: 0.237
  3. The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network. Cancer Epidemiol Biomarkers Prev. 2020 03; 29(3):599-605.
    View in: PubMed
    Score: 0.223
  4. Metabolome-Wide Association Study of the Relationship Between Habitual Physical Activity and Plasma Metabolite Levels. Am J Epidemiol. 2019 11 01; 188(11):1932-1943.
    View in: PubMed
    Score: 0.220
  5. A comprehensive survey of genetic variation in 20,691 subjects from four large cohorts. PLoS One. 2017; 12(3):e0173997.
    View in: PubMed
    Score: 0.183
  6. Deep targeted sequencing of 12 breast cancer susceptibility regions in 4611 women across four different ethnicities. Breast Cancer Res. 2016 11 05; 18(1):109.
    View in: PubMed
    Score: 0.179
  7. Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. Breast Cancer Res Treat. 2016 Feb; 155(3):531-40.
    View in: PubMed
    Score: 0.169
  8. Meta-Analysis of Rare Variant Association Tests in Multiethnic Populations. Genet Epidemiol. 2016 Jan; 40(1):57-65.
    View in: PubMed
    Score: 0.168
  9. Premenopausal plasma carotenoids, fluorescent oxidation products, and subsequent breast cancer risk in the nurses' health studies. Breast Cancer Res Treat. 2015 Jun; 151(2):415-25.
    View in: PubMed
    Score: 0.161
  10. Premenopausal plasma ferritin levels, HFE polymorphisms, and risk of breast cancer in the nurses' health study II. Cancer Epidemiol Biomarkers Prev. 2014 Mar; 23(3):516-24.
    View in: PubMed
    Score: 0.147
  11. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Res. 2021 Aug 18; 23(1):86.
    View in: PubMed
    Score: 0.062
  12. Mendelian randomisation study of smoking exposure in relation to breast cancer risk. Br J Cancer. 2021 Aug 02.
    View in: PubMed
    Score: 0.062
  13. Circulating carotenoids and breast cancer among high-risk individuals. Am J Clin Nutr. 2021 03 11; 113(3):525-533.
    View in: PubMed
    Score: 0.060
  14. Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. J Natl Cancer Inst. 2021 03 01; 113(3):329-337.
    View in: PubMed
    Score: 0.060
  15. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
    View in: PubMed
    Score: 0.060
  16. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. Br J Cancer. 2021 02; 124(4):842-854.
    View in: PubMed
    Score: 0.060
  17. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):623-642.
    View in: PubMed
    Score: 0.060
  18. Genome-wide association study meta-analysis identifies three novel loci for circulating anti-Müllerian hormone levels in women. medRxiv. 2020 Nov 03.
    View in: PubMed
    Score: 0.059
  19. Low dose environmental radon exposure and breast tumor gene expression. BMC Cancer. 2020 Jul 28; 20(1):695.
    View in: PubMed
    Score: 0.058
  20. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Sci Rep. 2020 06 16; 10(1):9688.
    View in: PubMed
    Score: 0.057
  21. Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and Sphingomyelins and Ovarian Cancer Risk: A 23-Year Prospective Study. J Natl Cancer Inst. 2020 06 01; 112(6):628-636.
    View in: PubMed
    Score: 0.057
  22. Involvement of fine particulate matter exposure with gene expression pathways in breast tumor and adjacent-normal breast tissue. Environ Res. 2020 07; 186:109535.
    View in: PubMed
    Score: 0.057
  23. Prediagnostic 25-Hydroxyvitamin D Concentrations in Relation to Tumor Molecular Alterations and Risk of Breast Cancer Recurrence. Cancer Epidemiol Biomarkers Prev. 2020 06; 29(6):1253-1263.
    View in: PubMed
    Score: 0.057
  24. A Prospective Analysis of Circulating Plasma Metabolites Associated with Ovarian Cancer Risk. Cancer Res. 2020 03 15; 80(6):1357-1367.
    View in: PubMed
    Score: 0.056
  25. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nat Commun. 2020 01 16; 11(1):312.
    View in: PubMed
    Score: 0.056
  26. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. NPJ Breast Cancer. 2019; 5:38.
    View in: PubMed
    Score: 0.055
  27. Genome-wide association study of anti-Müllerian hormone levels in pre-menopausal women of late reproductive age and relationship with genetic determinants of reproductive lifespan. Hum Mol Genet. 2019 04 15; 28(8):1392-1401.
    View in: PubMed
    Score: 0.053
  28. Genome-wide association study of germline variants and breast cancer-specific mortality. Br J Cancer. 2019 03; 120(6):647-657.
    View in: PubMed
    Score: 0.052
  29. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019 01 03; 104(1):21-34.
    View in: PubMed
    Score: 0.052
  30. Metabolites Associated With the Risk of Incident Venous Thromboembolism: A Metabolomic Analysis. J Am Heart Assoc. 2018 11 20; 7(22):e010317.
    View in: PubMed
    Score: 0.051
  31. Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study. PLoS Med. 2018 09; 15(9):e1002644.
    View in: PubMed
    Score: 0.051
  32. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet. 2018 07; 50(7):968-978.
    View in: PubMed
    Score: 0.050
  33. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017 Dec; 49(12):1767-1778.
    View in: PubMed
    Score: 0.048
  34. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017 11 02; 551(7678):92-94.
    View in: PubMed
    Score: 0.048
  35. Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Res. 2016 09 01; 76(17):5103-14.
    View in: PubMed
    Score: 0.043
  36. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. Br J Cancer. 2016 Feb 02; 114(3):298-304.
    View in: PubMed
    Score: 0.042
  37. Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. J Clin Oncol. 2014 Oct 01; 32(28):3111-7.
    View in: PubMed
    Score: 0.038
  38. Physical activity and risk of endometrial adenocarcinoma in the Nurses' Health Study. Int J Cancer. 2014 Jun 01; 134(11):2707-16.
    View in: PubMed
    Score: 0.036
  39. Plasma carotenoid- and retinol-weighted multi-SNP scores and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):927-36.
    View in: PubMed
    Score: 0.035
  40. ß-Carotene 15,15'-monooxygenase 1 single nucleotide polymorphisms in relation to plasma carotenoid and retinol concentrations in women of European descent. Am J Clin Nutr. 2012 Dec; 96(6):1379-89.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.